Although the results of global clinical trials on mild to moderate sporadic and LRRK2-PD patients are yet to be announced (ClinicalTrials.gov Identifier: NCT04056689; NCT03710707; NCT03976349), our study showed that kinase inhibition using twice-weekly subcutaneous GNE-7915 regimen in our LRRK2 mutant knock-in mice over 18 consecutive weeks (equivalent to ~13 years in human) was well tolerated and did not cause any apparent physical abnormalities or increased mortality. The gene discussed is LRRK2; the disease is Parkinson disease.